Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2013, Article ID 612971, 9 pages
http://dx.doi.org/10.1155/2013/612971
Research Article

PPAR Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice

1Department of Pharmacology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China
2Department of Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, UT, USA
3Division of Nephrology and Hypertension, University of Utah and Veterans Affairs Medical Center, 30N 1900E, RM 4C224, Salt Lake City, UT 84132, USA

Received 10 October 2013; Revised 30 November 2013; Accepted 2 December 2013

Academic Editor: Guangrui Yang

Copyright © 2013 Ying Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Craven and F. R. DeRubertis, “Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozocin-induced diabetes,” Journal of Laboratory and Clinical Medicine, vol. 113, no. 6, pp. 674–681, 1989. View at Google Scholar · View at Scopus
  2. F. R. DeRubertis and P. A. Craven, “Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes,” The American Journal of Kidney Diseases, vol. 22, no. 5, pp. 727–735, 1993. View at Google Scholar · View at Scopus
  3. R. Ishibashi, I. Tanaka, M. Kotani et al., “Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions,” Kidney International, vol. 56, no. 2, pp. 589–600, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Schambelan, S. Blake, J. Sraer, M. Bens, M. P. Nivez, and F. Wahbe, “Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus,” Journal of Clinical Investigation, vol. 75, no. 2, pp. 404–412, 1985. View at Google Scholar · View at Scopus
  5. H. Schramek, E. Coroneos, and M. J. Dunn, “Interactions of the vasoconstrictor peptides, angiotensin II and endothelin-1, with vasodilatory prostaglandins,” Seminars in Nephrology, vol. 15, no. 3, pp. 195–204, 1995. View at Google Scholar · View at Scopus
  6. B. M. Chapnick, P. W. Paustian, E. Klainer, P. D. Joiner, A. L. Hyman, and P. J. Kadowitz, “Influence of prostaglandins E, A and F on vasoconstrictor responses to norepinephrine, renal nerve stimulation and angiotensin in the feline kidney,” Journal of Pharmacology and Experimental Therapeutics, vol. 196, no. 1, pp. 44–52, 1976. View at Google Scholar · View at Scopus
  7. F. Catella-Lawson, B. Mcadam, B. W. Morrison et al., “Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 2, pp. 735–741, 1999. View at Google Scholar · View at Scopus
  8. M. D. Breyer and R. M. Breyer, “Prostaglandin E receptors and the kidney,” The American Journal of Physiology—Renal Physiology, vol. 279, no. 1, pp. F12–F23, 2000. View at Google Scholar · View at Scopus
  9. E. P. Silldorff, S. Yang, and T. L. Pallone, “Prostaglandin E2 abrogates endothelin-induced vasoconstriction in renal outer medullary descending vasa recta of the rat,” Journal of Clinical Investigation, vol. 95, no. 6, pp. 2734–2740, 1995. View at Google Scholar · View at Scopus
  10. N. Kvirkvelia, M. McMenamin, K. Chaudhary, M. Bartoli, and M. P. Madaio, “Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells,” The American Journal of Physiology—Renal Physiology, vol. 304, no. 5, pp. F463–F470, 2013. View at Publisher · View at Google Scholar
  11. R. Nasrallah, H. Xiong, and R. L. Hébert, “Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2Akita type I diabetic mice,” The American Journal of Physiology—Renal Physiology, vol. 292, no. 1, pp. F278–F284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Makino, I. Tanaka, M. Mukoyama et al., “Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1757–1765, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Mohamed, C. Jayakumar, and G. Ramesh, “Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6,” Laboratory Investigation, vol. 93, pp. 933–945, 2013. View at Publisher · View at Google Scholar
  14. H. Chen, O. Charlat, L. A. Tartaglia et al., “Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice,” Cell, vol. 84, no. 3, pp. 491–495, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. G. H. Lee, R. Proenca, J. M. Montez et al., “Abnormal splicing of the leptin receptor in diabetic mice,” Nature, vol. 379, no. 6566, pp. 632–635, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, Z. Jia, S. Liu et al., “Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice,” The American Journal of Physiology—Renal Physiology, vol. 305, no. 11, pp. F1555–F1562, 2013. View at Publisher · View at Google Scholar
  17. Y. Guan, “Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome,” Journal of the American Society of Nephrology, vol. 15, no. 11, pp. 2801–2815, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Guan, J. Yang, L. Chen et al., “PPARs and female reproduction: evidence from genetically manipulated mice,” PPAR Research, vol. 2008, Article ID 723243, 8 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Zheng and Y. Guan, “Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?” Kidney International, vol. 72, no. 11, pp. 1301–1303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Miyazaki, E. Cersosimo, C. Triplitt, and R. A. DeFronzo, “Rosiglitazone decreases albuminuria in type 2 diabetic patients,” Kidney International, vol. 72, no. 11, pp. 1367–1373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Pistrosch, K. Herbrig, B. Kindel, J. Passauer, S. Fischer, and P. Gross, “Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients,” Diabetes, vol. 54, no. 7, pp. 2206–2211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Yang, D. Zhang, J. Li, X. Zhang, F. Fan, and Y. Guan, “Role of PPARγ in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential,” Clinical Science, vol. 116, no. 1, pp. 17–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zhou, G. Liu, Z. Jia et al., “Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters,” The American Journal of Physiology—Renal Physiology, vol. 305, no. 10, pp. F1491–F1497, 2013. View at Publisher · View at Google Scholar
  24. Z. Jia, H. Wang, and T. Yang, “Microsomal prostaglandin e synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction,” Hypertension, vol. 59, no. 1, pp. 122–128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Paliege, D. Mizel, C. Medina et al., “Inhibition of nNOS expression in the macula densa by COX-2-derived prostaglandin E2,” The American Journal of Physiology—Renal Physiology, vol. 287, no. 1, pp. F152–F159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos, “Metabolic syndrome: definitions and controversies,” BMC Medicine, vol. 9, article 48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Ninichuk, A. G. Khandoga, S. Segerer et al., “The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice,” The American Journal of Pathology, vol. 170, no. 4, pp. 1267–1276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Ninichuk, O. Kulkarni, S. Clauss, and H. Anders, “Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy,” European Journal of Medical Research, vol. 12, no. 8, pp. 351–355, 2007. View at Google Scholar · View at Scopus
  29. A. Dey, R. S. Williams, D. M. Pollock et al., “Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria,” Obesity Research, vol. 12, no. 8, pp. 1278–1289, 2004. View at Google Scholar · View at Scopus
  30. H. Yki-Jarvinen, “ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” Current Diabetes Reports, vol. 7, no. 3, pp. 173–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Sosnowski and E. Janeczko-Sosnowska, “Commentary to the article: Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–43,” Kardiologia Polska, vol. 65, no. 2, pp. 214–217, 2007. View at Google Scholar
  32. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Ye, H. J. Zhang, A. Xu, and R. L. Hoo, “Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone,” PLoS ONE, vol. 8, no. 6, Article ID e65543, 2013. View at Publisher · View at Google Scholar
  34. H. Chodavarapu, N. Grobe, H. K. Somineni, E. S. Salem, M. Madhu, and K. M. Elased, “Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion,” PLoS ONE, vol. 8, no. 4, Article ID e62833, 2013. View at Publisher · View at Google Scholar
  35. J. Tonelli, W. Li, P. Kishore et al., “Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes,” Diabetes, vol. 53, pp. 1621–1629, 2004. View at Google Scholar
  36. E. Galkina and K. Ley, “Leukocyte recruitment and vascular injury in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 368–377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Furuta, T. Saito, T. Ootaka et al., “The role of macrophages in diabetic glomerulosclerosis,” The American Journal of Kidney Diseases, vol. 21, no. 5, pp. 480–485, 1993. View at Google Scholar · View at Scopus
  38. R. G. Parnova, “Molecular mechanisms of action of prostaglandin E2 in the regulation of water osmotic permeability,” Membrane and Cell Biology, vol. 13, no. 2, pp. 287–301, 2000. View at Google Scholar · View at Scopus
  39. Z. Jia, G. Liu, Y. Sun et al., “mPGES-1-derived PGE2 mediates dehydration natriuresis,” The American Journal of Physiology—Renal Physiology, vol. 304, no. 2, pp. F214–F221, 2013. View at Publisher · View at Google Scholar
  40. Z. Jia, G. Liu, M. Downton, Z. Dong, A. Zhang, and T. Yang, “mPGES-1 deletion potentiates urine concentrating capability after water deprivation,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 8, pp. F1005–F1012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Jia, T. Aoyagi, D. E. Kohan, and T. Yang, “mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite,” The American Journal of Physiology—Renal Physiology, vol. 299, no. 1, pp. F155–F166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Jia, T. Aoyagi, and T. Yang, “MPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP,” Hypertension, vol. 55, no. 2, pp. 539–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. Z. Jia, H. Wang, and T. Yang, “Mice lacking mPGES-1 are resistant to lithium-induced polyuria,” The American Journal of Physiology—Renal Physiology, vol. 297, no. 6, pp. F1689–F1696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Soodvilai, Z. Jia, M. H. Wang, Z. Dong, and T. Yang, “mPGES-1 deletion impairs diuretic response to acute water loading,” The American Journal of Physiology—Renal Physiology, vol. 296, no. 5, pp. F1129–F1135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Flores, Y. Liu, W. Liu, L. M. Satlin, and R. Rohatgi, “Flow-induced prostaglandin E2 release regulates Na and K transport in the collecting duct,” The American Journal of Physiology—Renal Physiology, vol. 303, no. 5, pp. F632–F638, 2012. View at Publisher · View at Google Scholar